Shares of Cuprina Holdings surged 45.9% to $5.75 in pre-market trading Tuesday, extending a wild run that began when the Singapore-based biomedical company dodged a NASDAQ delisting just two weeks ago. For shareholders who watched the stock languish below $0.30 in late May, the rebound feels dramatic — but the gap between the stock price and the underlying business has rarely been wider.
A Reverse Split and a Last-Minute Save Kept the Lights On
Cuprina failed to maintain NASDAQ's $1.00 minimum share price for 30 consecutive business days and missed its 180-day cure deadline on May 26, triggering a formal delisting determination.
The company executed a 1-for-8 reverse stock split on May 27 — combining every eight shares into one — to mechanically boost its price.
On June 11, NASDAQ confirmed Cuprina had regained compliance, and the July 7 delisting hearing was cancelled. The listing is saved, but a reverse split does nothing to improve a company's actual value; it just shrinks the share count.
An FDA Clearance Added Real Fuel to the Fire
On June 15, Cuprina announced its subsidiary received FDA clearance for its wound-care larvae product — the first of its kind using the Lucilia cuprina species.
Shares jumped over 110% on the news.
The clearance gives Cuprina U.S. commercial rights to both maggot species used in wound debridement therapy , a niche but growing area as antibiotic resistance pushes clinicians toward biological alternatives. This is the one genuine business catalyst in the mix.
The Financials Tell a Very Different Story
Cuprina carries negative equity of about -$4.46 million, with liabilities far exceeding assets.
Revenue is tiny at roughly $49,894, yet the stock trades at a price-to-sales ratio near 229x — meaning investors are paying roughly $229 for every $1 the company earns. Revenue dropped 40% in the first half of 2025, with a net loss of $1.528 million.
The company has just 10 employees and a market cap of roughly $12 million.
Momentum Trading, Not Fundamentals, Is Driving This
CUPR has exploded from sub-$0.30 in late May to above $6, showcasing extreme momentum trading.
Analysts flag weak financial performance, widening losses, and sharply higher cash burn as core risks. Today's spike comes with no fresh company-specific news — just traders riding residual volatility. The FDA clearance is real progress, but a stock that has moved 2,000%+ in a month on under $50,000 in revenue is priced entirely on speculation, not substance. Latecomers should approach with extreme caution.